Camera-based imaging technique offers objective alternative to manual skin assessment in scleroderma

For more than half a century, doctors have diagnosed and monitored scleroderma by doing something remarkably simple: pinching the skin between their fingers. The disease itself—a rare autoimmune condition that causes the body to overproduce collagen—hardens and thickens skin and internal organs. But the tool for measuring that hardening has remained unchanged since the 1970s. A physician's touch, their judgment about how resistant the skin feels, their sense of how much it has tightened since the last visit. The problem is obvious: two doctors examining the same patient will score the skin differently. One person's firm might be another's moderate. Over months or years, it becomes nearly impossible to know whether a patient is actually improving or whether the variation is simply the gap between one clinician's hands and another's.

Researchers at Boston University have now developed an alternative. Spatial frequency domain imaging, or SFDI, uses harmless light patterns projected onto the skin to measure its thickness and scarring without any physical contact. The light bounces back in measurable ways, and those readings correlate directly with the amount of collagen buildup visible in skin biopsies, with ultrasound measurements of skin depth, and with the traditional clinical scores doctors have been using all along. For the first time, there is a way to track what is actually happening beneath the surface—objectively, repeatably, and without the subjectivity that has always clouded the picture.

Darren Roblyer, a professor of biomedical engineering at Boston University, has been developing SFDI technology for nearly fifteen years. This is the first application of the technique to scleroderma. The research team, led by rheumatologist Andreea Bujor at Boston Medical Center, studied forty-nine people with scleroderma and twenty-five healthy volunteers. They imaged six sites across the hands, forearms, and fingers, then compared the light readings against multiple reference points: the doctor's traditional skin score, ultrasound thickness measurements, a handheld device that measures skin hardness, and actual skin biopsies from thirty-four patients and sixteen healthy controls. In eleven patients, they repeated the measurements over time to see whether SFDI could track changes as the disease progressed or as patients responded to treatment.

The results were striking. Light readings were consistently lower in people with scleroderma than in healthy individuals. Lower readings corresponded with higher clinical skin scores—meaning thicker, more fibrotic skin. The imaging also detected subtle changes in skin that doctors had scored as normal during physical examination, suggesting SFDI can catch disease progression before it becomes apparent to the human hand. This matters because scleroderma has no approved therapies specifically targeting skin fibrosis. Drug developers have struggled to prove that experimental treatments work, partly because the measurement tools available are too imprecise and too subjective. A therapy might actually be helping, but the variation in how different clinicians score skin thickness can mask that benefit in clinical trials.

Bujor, who is both a researcher and a practicing rheumatologist, sees the practical implications clearly. A fast, painless, non-contact measurement could transform how doctors monitor their patients over time. It could make clinical trials far more reliable at detecting whether a new drug is actually working. It could identify skin changes early, before they become severe enough to feel under a doctor's fingers. The findings, published in The Lancet Rheumatology, represent the first objective imaging standard for a disease that has relied on subjective assessment for decades. The work was supported by the National Scleroderma Foundation, the National Institutes of Health, and the Scleroderma Clinical Trials Consortium. What comes next is the harder part: moving this technology from the research lab into clinical practice, and then into the drug development pipeline where it could finally give researchers a reliable way to measure whether new treatments actually work.